Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Sells $70,500.00 in Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) Director Peter M. Neupert sold 10,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.05, for a total value of $70,500.00. Following the completion of the transaction, the director now owns 224,690 shares of the company's stock, valued at $1,584,064.50. The trade was a 4.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT traded up $0.13 during mid-day trading on Wednesday, hitting $7.62. 2,454,883 shares of the company's stock traded hands, compared to its average volume of 1,727,822. Adaptive Biotechnologies Co. has a 1 year low of $2.28 and a 1 year high of $8.95. The company has a market cap of $1.13 billion, a PE ratio of -6.99 and a beta of 1.53. The firm's 50 day simple moving average is $7.63 and its 200 day simple moving average is $6.09.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same quarter in the previous year, the business posted ($0.30) earnings per share. On average, research analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ADPT. The Goldman Sachs Group upped their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Piper Sandler restated an "overweight" rating and set a $11.00 target price (up from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Finally, Scotiabank boosted their price target on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.10.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ADPT. Ashton Thomas Securities LLC purchased a new stake in shares of Adaptive Biotechnologies during the third quarter worth about $34,000. KBC Group NV acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth approximately $50,000. Townsquare Capital LLC purchased a new stake in Adaptive Biotechnologies in the 3rd quarter worth approximately $56,000. GAMMA Investing LLC purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $59,000. Finally, Cibc World Markets Corp acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $65,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.